News
Morbidly obese patients remain an unsolved clinical problem,” explained co-author Gwo-Chin Lee, M.D., a hip and knee replacement surgeon at HSS. “Traditional weight loss measures have had mixed ...
US stocks edged higher on Monday as investors focused on tech's temporary reprieve from President Trump's tariffs. But on Sunday, US Commerce Secretary Howard Lutnick said that those electronics would ...
Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient ...
People taking GLP-1 drugs can decrease fat mass while minimizing muscle loss with a few key strategies that include proper ...
US stocks trimmed early session gains on Monday morning, as investors focused on tech's significant — if temporary — reprieve ...
US stocks edged higher Monday morning, as investors focused on tech's significant — if temporary — reprieve from President ...
Pfizer has axed its oral GLP-1 asset danuglipron after one patient had potential drug-induced liver injury in a phase 1 trial ...
Capping more than two years of stock-gyrating drama, Pfizer said Monday that it would stop development of danuglipron, its ...
17h
MarketBeat on MSN3 Safe Dividend Stocks as Investors Seek to Reset DiversificationOver the last three years, diversification has fallen out of fashion. When investors can make 20% or higher returns in ...
The decision to stop developing danuglipron adds to a string of setbacks in the pharmaceutical giant’s bid to win a slice of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results